GlaxoSmithKline maker of the diabetes drug, Avandia, announced today that it has settled more of the suits over the drug which many sources say led to a much increased risk of heart attack.

According to Reuters, the pharmaceutical company is keeping the terms of the settlement confidential and will also not confirm how many claims were settled. In May, Bloomberg reported that more than 700 Avandia suits were settled for about $86,000 each. This amount was lower than the approximately $500,000 predicted. Analysts believe that those earlier settlements, combined with the current claims, indicate the company may have less liability than first feared. “This implies that close to half of the cases have now been settled and should ease some fears about Vioxx-type liabilities,” said Deutsche Bank analyst Mark Clark.

Avandia is no longer a major product for GSK. After a highly critical Senate report was published in February, the company continues to be dogged by fears of increasing claims and liability. The FDA will convene an advisory panel in July to consider possible further restrictions on the drug.

Related Resources:

  • UPDATE 1-Glaxo settles first Avandia case due for trial (Reuters)
  • Glaxo Said to Pay $60 Million in Avandia Settlements (Bloomberg BusinessWeek)
  • California County Sues GSK over Diabetes Drug Avandia (FindLaw’s Injured)
  • Senate Report: Grave Concerns over Avandia, FDA (FindLaw’s Injured)
  • Why Drugs Get Pulled from the Market (FindLaw)
  • Personal Injuries from Dangerous or Defective Products (provided by Warner Law Offices PLLC)
  • Product Libility Overview (provided by Farmer, Cline & Campbell, PLLC)

You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help

Civil Rights

Block on Trump’s Asylum Ban Upheld by Supreme Court

Criminal

Judges Can Release Secret Grand Jury Records

Politicians Can’t Block Voters on Facebook, Court Rules